Latest news with #BOSTON
Yahoo
2 days ago
- Business
- Yahoo
Biologic Therapeutics Market to Hit $794.5 Billion by 2029
"Driven by Rising Chronic Disease Burden and Breakthrough FDA Approvals, Biopharmaceutical Market Surges with Demand for Monoclonal Antibodies, Gene and Cell Therapies, and Innovative Vaccines" BOSTON, July 28, 2025 /PRNewswire/ -- According to the latest study from BCC Research, "Biologic Therapeutic Drugs: Technologies and Global Markets" is projected to increase from $499.2 billion in 2024 to reach $794.5 billion by the end of 2029, at a compound annual growth rate (CAGR) of 9.7% from 2024 through 2029. This report provides a comprehensive analysis of the global market for biologic therapeutic drugs, segmented by product type (such as mAbs vaccines, and cell and gene therapies), source (mammalian, microbial, others), application (oncology, autoimmune, and infectious diseases), and region (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). It explores key market trends, challenges, and ESG developments, and examines the emerging technologies shaping the industry. The report also includes a competitive landscape analysis with market share rankings and detailed profiles of leading companies. This report is particularly relevant now due to the growing demand for innovative therapies and the rapid advances in regenerative medicine. Increased investments and intensified research activities are accelerating the development of biologic drugs, while a surge in product approvals is expanding treatment options in many medical fields. These factors are collectively driving significant growth in the biologics market, making timely insights into trends, challenges, and competitive dynamics more critical than ever. The factors driving the market's growth include: Growing Demand for Biologics: Biologics are increasingly favored due to their high efficacy, targeted action, and ability to treat complex diseases like cancer and autoimmune disorders. Patients and healthcare providers are turning to these advanced therapies for better outcomes and fewer side effects. Rising Investments in Biopharmaceuticals: The biopharma sector is seeing a surge in funding from pharmaceutical companies, investors, and governments. These investments support research, clinical trials, and manufacturing infrastructure, accelerating the development and availability of biologic drugs. Product Development Collaborations and Agreements: Collaborations between biotech firms and large pharmaceutical companies are common, enabling shared expertise, reduced costs, and faster product development. Licensing deals and joint ventures also help expand market reach and streamline commercialization. Transition Toward Personalized Medicines: Biologics are central to the shift toward personalized medicine, where treatments are tailored to individual genetic profiles. Advances in genomics and diagnostics enable more precise therapies, reducing trial-and-error in treatment. Aging Population and the Prevalence of Chronic Diseases: An aging global population is leading to a higher incidence of chronic diseases such as diabetes, cancer, and arthritis. Biologics offer effective long-term treatment options for these conditions, making them essential in managing the health needs of older adults. Request a sample copy of the global market for biologic therapeutic drugs report. Report Synopsis Report Metric Details Base year considered 2023 Forecast period considered 2024-2029 Base year market size $456.9 billion Market size forecast $794.5 billion Growth rate CAGR of 9.7% for the forecast period of 2024-2029 Segments covered Type, Source, Application, Region Regions covered North America, Europe, Asia-Pacific, Rest of the World(South America and the Middle East and Africa). Countries covered U.S., Canada, Mexico, U.K., Germany, France, Spain, Italy,China, India, Japan, Australia. Market drivers Growing Demand for Biologics Rising Investments in Biopharmaceuticals Product Development Collaborations andAgreements Transition Toward Personalized Medicines Rising Aging Population and the Growing Prevalenceof Chronic Diseases Interesting facts: The biologic therapeutics market is witnessing higher number of approvals for several new therapies and an increase in biologics approvals yearly. In 2023, the market witnessed approvals for breakthrough therapies such as gene editing therapy Casgevy from CRISPR Therapeutics and Vertex Pharmaceuticals and Leqembi (lecanemab) from Eisai for Alzheimer's disease. Emerging startups Arcus Biosciences Allogene Therapeutics Astria Therapeutics Bean Therapeutics HiFiBiO Therapeutics The report addresses the following questions: 1. What is the projected size and growth rate of the market? The global market for biologic therapeutic drugs was valued at $456.9 billion in 2023 and is expected to grow at a CAGR of 9.7% from 2024 to 2029 to reach $794.5 billion by the end of 2029. 2. What factors are driving the growth of the market? The global market for biologics therapeutic drugs is growing due to the world's rising aging population and the growing prevalence of chronic diseases, increasing numbers of product launches, and high demand for personalized medicine. 3. Which market segments are covered in the report? The global market for biologics therapeutic drugs is segmented based on product type, source, application, and region. 4. Which product type segment will be dominant through 2029? The monoclonal antibodies (mAbs) segment will dominate the market through 2029. 5. Which region has the largest market share? North America holds the largest share of the market. Market leaders include: ABBVIE INC. AMGEN INC. ASTRAZENECA BRISTOL-MYERS SQUIBB CO. ELI LILLY AND CO. F. HOFFMANN-LA ROCHE LTD. GILEAD SCIENCES INC. GSK PLC. JOHNSON & JOHNSON SERVICES INC. MERCK & CO. INC. NOVARTIS AG NOVO NORDISK A/S PFIZER INC. REGENERON PHARMACEUTICALS INC. SANOFI Related reports: Antibody Drugs: Technologies and Global Markets: This report provides reviews the global antibody drug market, focusing on monoclonal antibodies (mAbs) used in treating chronic diseases like cancer and autoimmune disorders. It covers market trends, regional analysis, and key companies. Forecasts extend to 2029, highlighting growth in therapeutic applications and technological advances. Purchase a copy of the report direct from BCC Research. For further information on any of these reports or to make a purchase, contact info@ About BCC Research BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype. Contact Us Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USA Email: info@ Phone: +1 781-489-7301 For media inquiries, email press@ or visit our media page for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. Logo - View original content to download multimedia: SOURCE BCC Research LLC Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CTV News
4 days ago
- Entertainment
- CTV News
Company involved in Coldplay KissCam drama hires Gwyneth Paltrow as spokesperson
Gwyneth Paltrow arrives at the 11th Breakthrough Prize Ceremony on Saturday, April 5, 2025, in Los Angeles. (Photo by Jordan Strauss/Invision/AP, File) BOSTON — Astronomer — the company whose CEO resigned after being caught on a KissCam at a Coldplay rock concert embracing a woman who was not his wife — is trying to move on from the drama with someone who knows the band pretty well. Actress Gwyneth Paltrow, who was married to Coldplay's frontman Chris Martin for 13 years, announced Friday on X that she has been hired by Astronomer as a spokesperson. Astronomer, a tech company based in New York, found itself in an uncomfortable spotlight when two of its executives were caught on camera in an intimate embrace at a Coldplay concert — a moment that was then flashed on a giant screen in the stadium. CEO Andy Byron and human resource executive Kristin Cabot were caught by surprise when Martin asked the cameras to scan the crowd during a concert earlier this month. 'Either they're having an affair or they're just very shy,' Martin joked when the couple appeared on screen and quickly tried to hide their faces. In a short video, the 'Shakespeare in Love' and 'Ironman' star said she had been hired as a 'very temporary' spokesperson for Astronomer. 'Astronomer has gotten a lot of questions over the last few days and they wanted me to answer the most common ones,' Paltrow said, smiling and deftly avoiding mention of the KissCam fuss. 'We've been thrilled that so many people have a newfound interest in data workflow automation,' she said. 'We will now be returning to what we do best — delivering game-changing results for our customers.' When footage from the KissCam first spread online, it wasn't immediately clear who the couple were. Soon after the company identified the pair, and Byron resigned followed by Cabot. The video clip resulted in a steady stream of memes, parody videos and screenshots of the pair's shocked faces filling social media feeds. Online streams of Coldplay's songs jumped 20 per cent in the days after the video went viral, according to Luminate, an industry data and analytics company.
CTV News
5 days ago
- Politics
- CTV News
U.S. judge blocks Trump's birthright citizenship restrictions in third ruling since high court decision
Demonstrators holds up a banner during a citizenship rally outside of the Supreme Court in Washington, May 15, 2025. (AP Photo/Jose Luis Magana, File) BOSTON — A U.S. federal judge on Friday blocked the Trump administration from ending birthright citizenship for the children of parents who are in the U.S. illegally, issuing the third court ruling blocking the birthright order nationwide since a key Supreme Court decision in June. U.S. District Judge Leo Sorokin, joining another district court as well as an appellate panel of judges, found that a nationwide injunction granted to more than a dozen states remains in force under an exception to the Supreme Court ruling. That decision restricted the power of lower-court judges to issue nationwide injunctions. The states have argued Trump's birthright citizenship order is blatantly unconstitutional and threatens millions of dollars for health insurance services that are contingent on citizenship status. The issue is expected to move quickly back to the nation's highest court. New Jersey Attorney General Matthew Platkin, who helped lead the lawsuit before Sorokin, said in a statement he was 'thrilled the district court again barred President Trump's flagrantly unconstitutional birthright citizenship order from taking effect anywhere.' 'American-born babies are American, just as they have been at every other time in our Nation's history,' he added. 'The President cannot change that legal rule with the stroke of a pen.' Lawyers for the government had argued Sorokin should narrow the reach of his earlier ruling granting a preliminary injunction, saying it should be 'tailored to the States' purported financial injuries.' Sorokin said a patchwork approach to the birthright order would not protect the states in part because a substantial number of people move between states. He also blasted the Trump administration, saying it had failed to explain how a narrower injunction would work. 'That is, they have never addressed what renders a proposal feasible or workable, how the defendant agencies might implement it without imposing material administrative or financial burdens on the plaintiffs, or how it squares with other relevant federal statutes,' the judge wrote. 'In fact, they have characterized such questions as irrelevant to the task the Court is now undertaking. The defendants' position in this regard defies both law and logic.' Sorokin acknowledged his order would not be the last word on birthright citizenship. Trump and his administration 'are entitled to pursue their interpretation of the Fourteenth Amendment, and no doubt the Supreme Court will ultimately settle the question,' Sorokin wrote. 'But in the meantime, for purposes of this lawsuit at this juncture, the Executive Order is unconstitutional.' The administration has not yet appealed any of the recent court rulings. Trump's efforts to deny citizenship to children born to parents who are in the country illegally or temporarily will remain blocked unless and until the Supreme Court says otherwise. An email asking for the White House's response to the ruling was sent Friday. A federal judge in New Hampshire issued a ruling earlier this month prohibiting Trump's executive order from taking effect nationwide in a new class-action lawsuit. U.S. District Judge Joseph LaPlante in New Hampshire had paused his own decision to allow for the Trump administration to appeal, but with no appeal filed in the last week, his order went into effect. On Wednesday, a San Francisco-based appeals court found the president's executive order unconstitutional and affirmed a lower court's nationwide block. A Maryland-based judge said this week that she would do the same if an appeals court signed off. The justices ruled last month that lower courts generally can't issue nationwide injunctions, but it didn't rule out other court orders that could have nationwide effects, including in class-action lawsuits and those brought by states. The Supreme Court did not decide whether the underlying citizenship order is constitutional. Plaintiffs in the Boston case earlier argued that the principle of birthright citizenship is 'enshrined in the Constitution,' and that Trump does not have the authority to issue the order, which they called a 'flagrantly unlawful attempt to strip hundreds of thousands of American-born children of their citizenship based on their parentage.' They also argue that Trump's order halting automatic citizenship for babies born to people in the U.S. illegally or temporarily would cost states funding they rely on to 'provide essential services' — from foster care to health care for low-income children, to 'early interventions for infants, toddlers, and students with disabilities.' At the heart of the lawsuits is the 14th Amendment to the Constitution, which was ratified in 1868 after the Civil War and the Dred Scott Supreme Court decision. That decision found that Scott, an enslaved man, wasn't a citizen despite having lived in a state where slavery was outlawed. The Trump administration has asserted that children of noncitizens are not 'subject to the jurisdiction' of the United States and therefore not entitled to citizenship. By Michael Casey. Associated Press reporter Mark Sherman in Washington contributed.
Associated Press
5 days ago
- Politics
- Associated Press
Judge blocks Trump's birthright citizenship restrictions in third ruling since high court decision
BOSTON (AP) — A federal judge on Friday blocked the Trump administration from ending birthright citizenship for the children of parents who are in the U.S. illegally, issuing the third court ruling blocking the birthright order nationwide since a key Supreme Court decision in June. U.S. District Judge Leo Sorokin, joining another district court as well as an appellate panel of judges, found that a nationwide injunction granted to more than a dozen states remains in force under an exception to the Supreme Court ruling. That decision restricted the power of lower-court judges to issue nationwide injunctions. The states have argued Trump's birthright citizenship order is blatantly unconstitutional and threatens millions of dollars for health insurance services that are contingent on citizenship status. The issue is expected to move quickly back to the nation's highest court. Lawyers for the government had argued Sorokin should narrow the reach of his earlier ruling granting a preliminary injunction, arguing it should be 'tailored to the States' purported financial injuries.' 'The record does not support a finding that any narrower option would feasibly and adequately protect the plaintiffs from the injuries they have shown they are likely to suffer,' Sorokin wrote.
Associated Press
7 days ago
- Business
- Associated Press
American Tower Corporation Releases 2024 Sustainability Executive Report
BOSTON--(BUSINESS WIRE)--Jul 23, 2025-- American Tower Corporation (NYSE: AMT) today announced the release of its 2024 sustainability executive report and accompanying indices and supplements, which highlight the Company's progress across its three sustainability pillars: Environment, Social, and Governance. The report underscores American Tower's commitment to aligning sustainability with operational excellence and long-term value creation. 'Our sustainability strategy is rooted in driving business value while addressing the evolving needs of our customers and communities,' said Steve Vondran, American Tower's President and Chief Executive Officer. 'Through initiatives like our energy program, digital access efforts and operational efficiency improvements, we're delivering measurable results that strengthen our business and create shared value for all stakeholders.' Key highlights from the 2024 report include: This year, American Tower also launched redesigned and enhanced sustainability webpages, providing stakeholders with a more dynamic and interactive platform to explore the Company's sustainability initiatives and progress. For more information on American Tower's sustainability program and to view the Company's 2024 Sustainability Executive Report and accompanying indices and supplements, please visit the 'Sustainability' portion of the Company's website at About American Tower American Tower, one of the largest global REITs, is a leading independent owner, operator and developer of multitenant communications real estate with a portfolio of over 149,000 communications sites and a highly interconnected footprint of U.S. data center facilities. For more information about American Tower, please visit Cautionary Language Regarding Forward-Looking Statements This press release contains 'forward-looking statements' concerning the Company's goals, beliefs, expectations, strategies, objectives, plans, future operating results and underlying assumptions and other statements that are not necessarily based on historical facts. Actual results may differ materially from those indicated in the Company's forward-looking statements as a result of various factors, including those factors set forth under the caption 'Risk Factors' in Item 1A of its most recent annual report on Form 10-K, and other risks described in documents the Company subsequently files from time to time with the Securities and Exchange Commission. The Company undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances. View source version on CONTACT: Kate Reeb Senior Director, Investor Relations Telephone: (617) 375-7565 KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS INDUSTRY KEYWORD: ENVIRONMENT COMMERCIAL BUILDING & REAL ESTATE TECHNOLOGY CONSTRUCTION & PROPERTY STEEL REIT SUSTAINABILITY MANUFACTURING INTERNET DATA MANAGEMENT SOURCE: American Tower Corporation Copyright Business Wire 2025. PUB: 07/23/2025 09:18 AM/DISC: 07/23/2025 09:18 AM
